Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, double blind, controlled phase I trial of the safety, tolerability and immunogenicity of Fluzone inactivated trivalent influenza virus vaccine administered with ascending doses of JVRS-100 adjuvant

Next Previous
Trial Profile

Randomized, double blind, controlled phase I trial of the safety, tolerability and immunogenicity of Fluzone inactivated trivalent influenza virus vaccine administered with ascending doses of JVRS-100 adjuvant

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JVRS 100 (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Juvaris BioTherapeutics

Most Recent Events

  • 15 Mar 2010 Company added as trial sponsor as reported by ClinicalTrials.gov.
  • 15 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 27 Apr 2009 Results will be presented at the National Foundation for Infectious Diseases 12th Annual Conference on Vaccine Research, according to a Juvaris BioTherapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top